This article compares two approaches side by side to clarify how they differ in principle and practice. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Intracavitary hypothermia describes controlled temperature therapy delivered directly into a body cavity such as the bladder, and is generally positioned as an adjunct intended to enhance the penetration of intravesical chemotherapy. Thermal methods dominate the field: radiofrequency ablation (RFA) and microwave ablation (MWA) heat tissue to cytotoxic temperatures, while cryoablation instead freezes the target to lethal cold. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team.
Cryoablation vs Microwave ablation: Key Differences
Cryoablation uses lethal cold and produces an ice ball that is often visible on imaging, whereas microwave ablation uses heat and generally creates its zone more rapidly. The visibility of the freezing margin is sometimes cited as helpful near sensitive structures, while heat-based ablation may offer shorter application times in certain settings. Each carries its own considerations, such as bleeding risk profiles and effects near vessels, which are weighed per patient. Modality choice is determined by the treating physician according to tumor type, location, and clinical goals.
How INVAMED Supports Both Approaches
INVAMED groups its ablation portfolio by the energy modality and anatomical target, offering radiofrequency platforms for soft tissue and bone as well as an intracavitary hypothermia set. Each device is intended for use by trained clinicians under appropriate image guidance and per the instructions for use (IFU). For intravesical therapy, the HyperTiss Intracavitary Hypothermia Set is positioned for adjunctive use alongside intravesical chemotherapy in bladder cancer. Generator specifications, applicator and antenna options, and compatible accessories are provided in product documentation, and buyers should request the relevant IFU for each variant.
Key Considerations
- Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone.
- Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
- Achieving an adequate ablation margin is widely emphasized in the literature for durable local tumor control, and may call for overlapping applications in larger lesions.
Frequently Asked Questions
What radiofrequency ablation systems does INVAMED offer?
INVAMED offers the Peta RFA System, positioned for soft-tissue, liver, and nerve applications, the multi-application ThermoEdge RFA Platform, and the Fusion Intraosseous RFA System for spinal tumors.
What determines the ablation zone size?
Published sources note that factors such as generator power, applicator design, application time, and local blood flow influence the ablation zone, and settings are selected by the treating physician.
How is microwave ablation different from radiofrequency ablation?
Both are heat-based, but microwave ablation is often described as heating tissue faster and being less affected by the heat-sink effect near vessels, while RFA has a particularly deep evidence base; the choice is made by the clinician.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
INVAMED's HyperTiss Intracavitary Hypothermia Set for Bladder Cancer Treatment is an intravesical temperature-therapy set positioned for adjunctive use alongside intravesical chemotherapy for bladder cancer. All INVAMED ablation devices are intended for use by trained clinicians under appropriate image guidance and in accordance with the IFU. Achieving an adequate ablation margin around the tumor is a recognized goal in the literature, and the treating clinician judges whether a single or overlapping-ablation approach is warranted. INVAMED's Peta Radiofrequency Ablation (RFA) System is a generator-based ablation platform offered in variants for soft-tissue and liver tumor ablation as well as nerve (pain) ablation, and the multi-application ThermoEdge RFA Platform is positioned for liver and kidney tissue resection, cysts, and endometrial ablation.
Important Disclaimer
This article is intended for general educational and technical information about medical device technologies. It is not medical advice, a diagnosis, or a treatment recommendation, and it does not replace consultation with a qualified healthcare professional. Any decision about diagnosis or treatment should be made by a licensed clinician based on an individual assessment. INVAMED devices are intended for use by trained healthcare professionals in accordance with the applicable Instructions for Use (IFU) and local regulatory approvals. Product availability and indications vary by country.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.